Bonesupport Holding AB Stock

Equities

BONEX

SE0009858152

Pharmaceuticals

Market Closed - Nasdaq Stockholm 11:29:57 2024-05-24 am EDT 5-day change 1st Jan Change
257.6 SEK +1.74% Intraday chart for Bonesupport Holding AB +6.18% +36.88%
Sales 2024 * 857M 80.35M Sales 2025 * 1.19B 111M Capitalization 16.93B 1.59B
Net income 2024 * 174M 16.32M Net income 2025 * 311M 29.16M EV / Sales 2024 * 19.5 x
Net cash position 2024 * 239M 22.41M Net cash position 2025 * 488M 45.76M EV / Sales 2025 * 13.8 x
P/E ratio 2024 *
99.1 x
P/E ratio 2025 *
54.2 x
Employees 121
Yield 2024 *
-
Yield 2025 *
0.38%
Free-Float 90.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.74%
1 week+6.18%
Current month+13.98%
1 month+5.75%
3 months+33.13%
6 months+56.12%
Current year+36.88%
More quotes
1 week
241.60
Extreme 241.6
258.60
1 month
216.20
Extreme 216.2
258.60
Current year
172.50
Extreme 172.5
258.60
1 year
110.20
Extreme 110.2
258.60
3 years
34.20
Extreme 34.2
258.60
5 years
19.05
Extreme 19.05
258.60
10 years
9.04
Extreme 9.04
258.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 18-02-28
Director of Finance/CFO 61 18-10-31
Chief Operating Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 66 -
Chairman 69 17-02-28
Director/Board Member 68 16-08-31
More insiders
Date Price Change Volume
24-05-24 257.6 +1.74% 108,348
24-05-23 253.2 -1.40% 55,259
24-05-22 256.8 +2.31% 67,596
24-05-21 251 +2.70% 100,616
24-05-20 244.4 +0.74% 95,631

Delayed Quote Nasdaq Stockholm, May 24, 2024 at 11:29 am EDT

More quotes
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
257.6 SEK
Average target price
292.7 SEK
Spread / Average Target
+13.61%
Consensus

Quarterly revenue - Rate of surprise